Skip to content
DraconiticResearch
Search Sources API
186,625 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BYBiomedicines

Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Chronic Kidney Disease of Predominantly Glomerular Origin: A Two-Year Comparative Cohort Study with Historical Controls

  • Veronica Aladzhova1
  • Teodora Ilieva1
  • Bilyana Vasileva1
  • Mariana Petkova1
  • Martin Milkinski1
  • Simona Kuzmanova-Hrischeva1
  • Simona Kerezieva1
  • Ina Georgieva1
  • Ivan Trendafilov1
  • Maria Radanova2
  • Vasil Vasilev1
  1. 1Department of Nephrology, Medical Faculty, , 1431 Sofia, Bulgaria; (V.A.); (T.I.); (B.V.); (M.P.); (M.M.); (S.K.-H.); (S.K.); (I.G.); (I.T.)
  2. 2Department of Biochemistry, Molecular Medicine and Nutrigenomics, Faculty of Pharmacy, , 9002 Varna, Bulgaria;
Read full textPDFCite

Related

  1. Comparative Efficacy and Safety of Saroglitazar and Dapagliflozin on Hepatic Steatosis and Glycemic Control in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A 25-Week Prospective Multicenter Comparative Cohort Study.
    Mukulesh Gupta, Kumar Prafull Chandra, Rajiv Awasthi +4
    Endocrinology, diabetes & metabolismPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  2. Symptoms improvement and lung function benefits of fixed triple therapy with beclomethasone/formoterol/glycopyrronium inhalation powder in patients with moderate-to-severe COPD: outcomes of the Bulgarian arm of the RESPONSE study
    Rosen E. Petkov, Andrey N. Kenderov, Neli L. Rodopska +2
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease
    Cheng Gong, Qiong Luo, Qin Li
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Early Initiation of Dapagliflozin in Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Abdullah Almaqhawi, Ahmed K. Alsaif, Hamza Ashraf +8
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Antialbuminuric Effect of Dapagliflozin Correlates With Urinary Epidermal Growth Factor in Real-World Patients With Diabetic Kidney Disease
    Silvio Borrelli, Annapaola Coppola, Chiara Ruotolo +15
    Kidney medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{aladzhova2026realworld,
  title = {{Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Chronic Kidney Disease of Predominantly Glomerular Origin: A Two-Year Comparative Cohort Study with Historical Controls}},
  author = {Veronica Aladzhova and Teodora Ilieva and Bilyana Vasileva and Mariana Petkova and Martin Milkinski and Simona Kuzmanova-Hrischeva and Simona Kerezieva and Ina Georgieva and Ivan Trendafilov and Maria Radanova and Vasil Vasilev},
  journal = {Biomedicines},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13701937},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Chronic Kidney Disease of Predominantly Glomerular Origin: A Two-Year Comparative Cohort Study with Historical Controls
AU  - Veronica Aladzhova
AU  - Teodora Ilieva
AU  - Bilyana Vasileva
AU  - Mariana Petkova
AU  - Martin Milkinski
AU  - Simona Kuzmanova-Hrischeva
AU  - Simona Kerezieva
AU  - Ina Georgieva
AU  - Ivan Trendafilov
AU  - Maria Radanova
AU  - Vasil Vasilev
PY  - 2026
DA  - 2026/10/01
JO  - Biomedicines
UR  - https://europepmc.org/article/PMC/PMC13701937
SN  - 2227-9059
ER  -